BiotechTube

Ponesimod

Phase 3Recruiting
1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate-to-severe Chronic Plaque Psoriasis

Conditions

Moderate-to-severe Chronic Plaque Psoriasis

Trial Timeline

Jan 1, 2026 → Dec 1, 2028

NCT ID
NCT07362017

About Ponesimod

Ponesimod is a phase 3 stage product being developed by Vanda Pharmaceuticals for Moderate-to-severe Chronic Plaque Psoriasis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07362017. Target conditions include Moderate-to-severe Chronic Plaque Psoriasis.

What happened to similar drugs?

2 of 8 similar drugs in Moderate-to-severe Chronic Plaque Psoriasis were approved

Approved (2) Terminated (0) Active (6)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅dupilumabSanofiApproved
🔄SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
🔄Indacaterol + ControlNovartisPhase 3
🔄Dupilumab + PlaceboSanofiPhase 3
🔄sufentanil sublingual tablet 30 mcgTalpheraPhase 3
🔄Zalviso™ 15 mcgTalpheraPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07362017Phase 3Recruiting

Competing Products

13 competing products in Moderate-to-severe Chronic Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
SHR-1314Jiangsu Hengrui MedicinePhase 1
25
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
SHR-1314 + PlaceboJiangsu Hengrui MedicinePhase 3
36
Indacaterol + ControlNovartisPhase 3
40
DeucravacitinibBristol Myers SquibbPre-clinical
33
Dupilumab + PlaceboSanofiPhase 3
40
dupilumabSanofiApproved
43
dupilumabSanofiPre-clinical
26
sufentanil sublingual tablet 30 mcgTalpheraPhase 3
30
Zalviso™ 15 mcgTalpheraPhase 3
30
sufentanil sublingual 30 mcg tabletTalpheraPhase 3
30